Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Treasury Shares (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Treasury Shares data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Treasury Shares rose 16.05% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 16.05%, while the annual FY2025 figure was $2.3 million, 16.05% up from the prior year.
  • Treasury Shares reached $2.3 million in Q4 2025 per TRDA's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.4 million in Q3 2025 and bottomed at $295104.0 in Q2 2022.
  • Average Treasury Shares over 4 years is $1.1 million, with a median of $689771.0 recorded in 2023.
  • The widest YoY moves for Treasury Shares: up 437.67% in 2025, down 78.21% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $463964.0 in 2022, then surged by 173.4% to $1.3 million in 2023, then soared by 55.18% to $2.0 million in 2024, then increased by 16.05% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.3 million in Q4 2025, $2.4 million in Q3 2025, and $438500.0 in Q2 2025.